At least 2 antisera were used for each antigen tested. The HLA AIO antigen embraces the specificities A25 and A26, which we shall list in parentheses when the antigen could be further defined. Initial testing for AIO and A25 included one antiserum from NIH and one antiserum from the Red Cross for each antigen; both antisera against A26 were from Red Cross sources. Five additional antisera were used in an effort to try to define further the AIO antigen in cells of available subjects and parents who had both AIO and B18 antigen. B18 antigen was determined with antisera from NIH and the American Red Cross.
C2 activity was determined by previously published methods.6 Normal C2 levels for this laboratory had been determined from 62 normal young adults. In addition the range of C2Dhet activity was determined from a group of 9 obligate heterozygotes including parents and children of C2Dhom individuals. In order to assess the possible genetic transmission of the low C2 activity and its association with the haplotype AIO, B18, C2 assays and HLA typing were performed on available parents of Red Cross donors whose C2 levels were in the obligate heterozygote range. All C2 activities were determined and C2Dhet individuals identified without prior knowledge of any individual's tissue type. Appropriate controls were included each time C2 activity was determined.
All subjects were AIO and/or B18 antigens were questioned about a history of arthritis, skin rashes, sun sensitivity, Raynaud's phenomenon, or unexplained fever. In subjects with low C2 levels, Cls inhibitor and C4 protein levels were determined by Mancini radial immunodiffusion tests,10 antinuclear antibodies were measured by a fluorescent method using mouse liver as the substrate, and rheumatoid factor was measured by latex fixation testing.
Results
C2 activity ranges and number of individuals with C2Dhet are listed in Table 1 
Discussion
An association of C2D with tissue antigens A10 and B18 was expected on the basis of previous reports concerning C2D in families usually identified by a propositus with C2Dhom and connective tissue disease.' However, it was impressive to find that among the individuals in an apparently normal population at least 6255% of those with AIO, B18 haplotype were C2Dhet. The AIO, B18 haplotypes of these 5 individuals were established by family studies (Table 2) . From these data we can estimate, with 95% confidence limits, that between 24 5%o
and 91-5y% of individuals with an AIO, B18 haplotype carry the null C2 gene. The estimate could be even higher if the Al0 and B18 tissue antigens in any of the other 3 individuals with normal C2 levels are not present as a haplotype. The frequency found is similar to an estimate in a Danish population in which family studies were not performed for most subjects.-" It was equally striking in our study that all individuals who were C2Dhet had an AI0, B18 haplotype. Although C2D was not associated with other haplotypes in our study, it has occurred with other haplotypes in some families in which the propositus has C2Dhom associated with SLE. 4 The minimum frequency of C2Dhet among the full panel of 418 donors was 1 
